Goods and Bads of the Endocannabinoid System as a Therapeutic Target: Lessons Learned after 30 Years

doi:10.1124/pharmrev.122.000600

KMS > iHuman研究所

	Goods and Bads of the Endocannabinoid System as a Therapeutic Target: Lessons Learned after 30 Years
	Maccarrone, Mauro 1,2,14; Di Marzo, Vincenzo 3; Gertsch, Jurg 4; Grether, Uwe 5; Howlett, Allyn C.6; Hua, Tian7 ; Makriyannis, Alexandros 8,9; Piomelli, Daniele 10,11; Ueda, Natsuo 12; van der Stelt, Mario 13
	2023-09-01
发表期刊	PHARMACOLOGICAL REVIEWS (IF:19.3[JCR-2023],22.1[5-Year])
ISSN	0031-6997
EISSN	1521-0081
卷号	75 期号:5
发表状态	已发表
DOI	10.1124/pharmrev.122.000600
摘要	The cannabis derivative marijuana is the most widely used recreational drug in the Western world and is consumed by an estimated 83 million indi-viduals (-3% of the world population). In recent years, there has been a marked transformation in society re-garding the risk perception of cannabis, driven by its le-galization and medical use in many states in the United States and worldwide. Compelling research evidence and the Food and Drug Administration cannabis-derived cannabidiol approval for severe childhood epilepsy have confirmed the large therapeutic potential of cannabidiol itself, D9-tetrahydrocannabinol and other plant-derived cannabinoids (phytocannabinoids). Of note, our body has a complex endocannabinoid system (ECS)-made of receptors, metabolic enzymes, and transporters- that is also regulated by phytocannabinoids. The first en-docannabinoid to be discovered 30 years ago was ananda-mide (N-arachidonoyl-ethanolamine); since then, distinct elements of the ECS have been the target of drug design programs aimed at curing (or at least slowing down) a number of human diseases, both in the central nervous system and at the periphery. Here a critical review of our knowledge of the goods and bads of the ECS as a therapeu-tic target is presented to define the benefits of ECS-active phytocannabinoids and ECS-oriented synthetic drugs for human health.Significance Statement--The endocannabinoid system plays important roles virtually everywhere in our body and is either involved in mediating key pro-cesses of central and peripheral diseases or represents a therapeutic target for treatment. Therefore, under-standing the structure, function, and pharmacology of the components of this complex system, and in particu-lar of key receptors (like cannabinoid receptors 1 and 2) and metabolic enzymes (like fatty acid amide hydrolase and monoacylglycerol lipase), will advance our under-standing of endocannabinoid signaling and activity at molecular, cellular, and system levels, providing new op-portunities to treat patients.
URL	查看原文
收录类别	SCI
语种	英语
资助项目	Italian Ministry of Health through the competitive Ricerca Finalizzata[RF-2018-12365391] ; National Institutes of Health National Institute on Drug Abuse[R01-DA042157] ; National Institute on Drug Abuse[P01-DA009158] ; National Institute on Alcohol Abuse and Alcoholism[U01-AA028963]
WOS研究方向	Pharmacology & Pharmacy
WOS类目	Pharmacology & Pharmacy
WOS记录号	WOS:001106811200002
出版者	AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS
引用统计	正在获取...
文献类型	期刊论文
条目标识符	https://kms.shanghaitech.edu.cn/handle/2MSLDSTB/347850
专题	iHuman研究所 iHuman研究所_PI研究组_华甜组
通讯作者	Maccarrone, Mauro
作者单位	1.Univ Aquila, Dept Biotechnol & Appl Clin Sci, Laquila, Italy 2.Santa Lucia Fdn, European Ctr Brain Res, Rome, Italy 3.Univ Laval, Canada Excellence Res Chair Microbiome Endocannabi, Quebec City, PQ, Canada 4.Univ Bern, Inst Biochem & Mol Med, NCCR TransCure, Bern, Switzerland 5.F Hoffmann La Roche Ltd, Roche Innovat Ctr Basel, Roche Pharm Res & Early Dev, Basel, Switzerland 6.Wake Forest Univ, Bowman Gray Sch Med, Dept Physiol & Pharmacol, Winston Salem, NC USA 7.ShanghaiTech Univ, iHuman Inst, Shanghai, Peoples R China 8.Northeastern Univ, Ctr Drug Discovery, Boston, MA USA 9.Northeastern Univ, Dept Pharmaceut Sci, Boston, MA USA 10.Univ Calif Irvine, Dept Pharmaceut Sci, Irvine, CA USA 11.Univ Calif Irvine, Dept Biol Chem, Irvine, CA USA 12.Kagawa Univ, Sch Med, Dept Biochem, Miki, Kagawa, Japan 13.Leiden Univ, Leiden Inst Chem, Dept Mol Physiol, Leiden, Netherlands 14.Univ Aquila, Dept Biotechnol & Appl Clin Sci, Via Vetoio Snc, I-67100 Laquila, Italy
推荐引用方式 GB/T 7714	Maccarrone, Mauro,Di Marzo, Vincenzo,Gertsch, Jurg,et al. Goods and Bads of the Endocannabinoid System as a Therapeutic Target: Lessons Learned after 30 Years[J]. PHARMACOLOGICAL REVIEWS,2023,75(5).
APA	Maccarrone, Mauro.,Di Marzo, Vincenzo.,Gertsch, Jurg.,Grether, Uwe.,Howlett, Allyn C..,...&van der Stelt, Mario.(2023).Goods and Bads of the Endocannabinoid System as a Therapeutic Target: Lessons Learned after 30 Years.PHARMACOLOGICAL REVIEWS,75(5).
MLA	Maccarrone, Mauro,et al."Goods and Bads of the Endocannabinoid System as a Therapeutic Target: Lessons Learned after 30 Years".PHARMACOLOGICAL REVIEWS 75.5(2023).